These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29127952)

  • 21. Diabetes mellitus secondary to glycogen storage disease type III.
    Oki Y; Okubo M; Tanaka S; Nakanishi K; Kobayashi T; Murase T
    Diabet Med; 2000 Nov; 17(11):810-2. PubMed ID: 11131107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.
    Fulcher G; Matthews DR; Perkovic V; de Zeeuw D; Mahaffey KW; Mathieu C; Woo V; Wysham C; Capuano G; Desai M; Shaw W; Vercruysse F; Meininger G; Neal B;
    Diabetes Obes Metab; 2016 Jan; 18(1):82-91. PubMed ID: 26450639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
    Rosenstock J; Aggarwal N; Polidori D; Zhao Y; Arbit D; Usiskin K; Capuano G; Canovatchel W;
    Diabetes Care; 2012 Jun; 35(6):1232-8. PubMed ID: 22492586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impaired Very-Low-Density Lipoprotein catabolism links hypoglycemia to hypertriglyceridemia in Glycogen Storage Disease type Ia.
    Hoogerland JA; Peeks F; Hijmans BS; Wolters JC; Kooijman S; Bos T; Bleeker A; van Dijk TH; Wolters H; Gerding A; van Eunen K; Havinga R; Pronk ACM; Rensen PCN; Mithieux G; Rajas F; Kuipers F; Reijngoud DJ; Derks TGJ; Oosterveer MH
    J Inherit Metab Dis; 2021 Jul; 44(4):879-892. PubMed ID: 33739445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of diabetes associated with glycogen storage disease type Ia.
    Yuan X; Ma W; Wu X; Xing X; Li Y; Wang O; Zhang H; Yang H
    Diabet Med; 2021 Feb; 38(2):e14373. PubMed ID: 32740965
    [No Abstract]   [Full Text] [Related]  

  • 26. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
    Vivian E
    Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: results of a worldwide, non-interventional, observational study data pool.
    Schnell O; Weng J; Sheu WH; Watada H; Kalra S; Soegondo S; Yamamoto N; Rathod R; Zhang C; Grzeszczak W
    J Diabetes Complications; 2016; 30(4):628-37. PubMed ID: 26935335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy].
    Kellerer M; Jakob S; Linn T; Haslbeck M
    MMW Fortschr Med; 2003 Dec; 145(51-52):I-X; quiz XI-XII. PubMed ID: 14974337
    [No Abstract]   [Full Text] [Related]  

  • 29. The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients.
    Duran C; Tuncel E; Ersoy C; Ercan I; Selimoglu H; Kiyici S; Guclu M; Erturk E; Imamoglu S
    J Endocrinol Invest; 2009 Jan; 32(1):69-73. PubMed ID: 19337019
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy.
    König M; Holzhütter HG
    J Biol Chem; 2012 Oct; 287(44):36978-89. PubMed ID: 22977253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistent hypoglycemia: Glycogen storage disease type Ib.
    Rabener MJ; Howell CM
    JAAPA; 2020 Apr; 33(4):1-3. PubMed ID: 32217911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-Glucose Cotransporters as Potential Therapeutic Targets in Patients With Type 1 Diabetes Mellitus: An Update on Phase 3 Clinical Trial Data.
    Patel K; Carbone A
    Ann Pharmacother; 2019 Dec; 53(12):1227-1237. PubMed ID: 31226886
    [No Abstract]   [Full Text] [Related]  

  • 35. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
    Tang H; Cui W; Li D; Wang T; Zhang J; Zhai S; Song Y
    Diabetes Obes Metab; 2017 Jan; 19(1):142-147. PubMed ID: 27598833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Obesity and reversed growth retardation in a child with type Ia glycogen storage disease.
    Karnsakul W; Gillespie S; Skitarelic K; Hummel M
    J Pediatr Endocrinol Metab; 2010 May; 23(5):507-12. PubMed ID: 20662351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can alpha-glucosidase inhibitors reduce the insulin dosage administered to patients with non-insulin-dependent diabetes mellitus?
    Okada S; Ishii K; Hamada H; Tanokuchi S; Ichiki K; Ota Z
    J Int Med Res; 1995; 23(6):487-91. PubMed ID: 8746617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liberal Glycemic Control in Critically Ill Patients With Type 2 Diabetes: An Exploratory Study.
    Kar P; Plummer MP; Bellomo R; Jenkins AJ; Januszewski AS; Chapman MJ; Jones KL; Horowitz M; Deane AM
    Crit Care Med; 2016 Sep; 44(9):1695-703. PubMed ID: 27315191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
    Inagaki N; Harashima S; Maruyama N; Kawaguchi Y; Goda M; Iijima H
    Cardiovasc Diabetol; 2016 Jun; 15():89. PubMed ID: 27316668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring.
    Hay LC; Wilmshurst EG; Fulcher G
    Diabetes Technol Ther; 2003; 5(1):19-26. PubMed ID: 12725703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.